Bringing doctors together

or

A free, private network for verified physicians

Leading voices

Dr. Shashank Sinha

Advanced Heart Failure · Inova Fairfax Hospital

View

Dr. Javed Butler

Advanced Heart Failure · Baylor Health Care System

View

Dr. Andrew Sauer

Advanced Heart Failure · Saint Luke's

View

Dr. Anu Lala

Advanced Heart Failure · Mount Sinai

View

Dr. Robert Mentz

Advanced Heart Failure · Duke University

View

Dr. Sunny Varshney

Advanced Heart Failure · Stanford

View

Dr. Stephanie Hsiao

Advanced Heart Failure · Stanford

View

Dr. Michelle Kittleson

Advanced Heart Failure · Cedars-Sinai

View

Dr. Adrian Hernandez

Advanced Heart Failure · Duke

View

Dr. Dorairaj Prabhakaran

General Cardiology

View
  • Discover your community

  • Stay current

  • A profile that represents you

  • Find your people

About RoonPrivacyTerms

    Overview

    Can't Rain on Our Parade: Highlights from the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2024.

    Oct 10, 2024DOI: 10.1016/j.cardfail.2024.10.001Journal ArticleJCF

    Written by: Alexander G HajduczokElena M DonaldJennifer ManingQuentin YoumansNosheen Reza

    Find these authors on Roon

    AH

    Dr. Alexander Hajduczok

    Advanced Heart Failure · Oklahoma Heart Hospital

    QY

    Dr. Quentin Youmans

    Advanced Heart Failure · Northwestern Medicine

    Late Breaking Clinical Research

    In the STEP-HFpEF trial, semaglutide was shown to improve HF-related health status and exercise function and reduce body weight (BW) in patients with obesity-related HFpEF1. The first prespecified analysis presented explored the efficacy and safety of semaglutide in patients with obesity-related HFpEF according to frailty status1. Results showed no difference in weight loss with semaglutide across frailty strata (−6.8% vs. −8.0 vs −8.8% change in BW with increasing frailty status, p=0.38). However, HF-related health status measured by the Kansas City Cardiomyopathy Questionnaire-12 Clinical Summary Score (KCCQ-CSS) did vary according to frailty status at 52 weeks with the greatest improvement seen among the most frail participants (p=0.03). A second prespecified analysis investigated the effects of semaglutide on endpoints across the range of exercise impairment measured by baseline 6-minute walk distance (6MWD). Overall, there were no differential effect on endpoints (reduced BW, improved 6MWD, and decreased CRP and NT-proBNP) across the spectrum of baseline 6MWD (i.e., consistent benefit). Women with the most severe impairment in exercise function (lowest baseline 6MWD tertile) appeared to derive the greatest health-related QOL benefit with semaglutide as measured by KCCQ-CSS (mean difference 13.2 vs 4.6 vs 4.6 points respectively for increasing tertile of baseline 6MWD; interaction p=0.028). Data presented demonstrate the benefits of semaglutide for improving HF-related symptoms and physical limitations even among a high-risk HFpEF population.The FINEARTS-HF trial showed that finerenone reduced the rate of a composite of total worsening HF (WHF) events and death from cardiovascular (CV) cause compared with placebo in patients with HF and a left ventricular ejection fraction (LVEF) of 40% or greater2. Newly presented data showed that the treatment effect was consistent across the spectrum of LVEF3. Furthermore, compared with those without recent WHF, patients with a recent WHF event were at higher risk for recurrent HF events and CV death and potentially also experienced a larger treatment benefit. Finerenone appeared to lower the risk of the primary composite to a greater extent in those enrolled within 7 days of WHF (RR: 0.74; 95% CI: 0.57-0.95) or between 7 days and 3 months of WHF (RR: 0.79; 95% CI: 0.64-0.97) than in those >3 months from WHF or without prior WHF (RR: 0.99; 95% CI: 0.81-1.21)4. These data add credence to the use of mineralocorticoid receptor antagonism in heart failure patients with LVEF >40%, and suggests enhanced absolute treatment benefit in those with recent WHF.The HELIOS-B trial demonstrated evidence for vutrisiran, an RNA interference therapeutic, in reducing all-cause mortality and recurrent CV events while preserving functional capacity and quality of life in both wild-type and variant transthyretin amyloidosis cardiomyopathy (ATTR-CM)5. Two exploratory analyses of this phase 3 double-blind randomized controlled trial (RCT were presented6,7. Both cardiac troponin I and NTproBNP are well-established prognostic biomarkers of increased mortality in ATTR-CM. In the present biomarker analysis, patients randomized to the vutrisiran had a 32% relative reduction in mean NT-proBNP level from baseline and a 32% relative reduction in mean troponin I level from baseline at 30 months compared to placebo, consistent across all prespecified subgroups. Vutrisiran was also shown to attenuate decline in LVEF (least squares mean difference 2.03%, 95% CI 0.34-3.73, p=0.019), absolute peak longitudinal strain (1.23%, 95% CI 0.73-1.73, p<0.0001) and LV stroke volume (4.05 mL, 95% CI 1.72-6.38, p=0.007) at 30 months compared to placebo. Encouraging effects were also seen in attenuating increases in mean LV wall thickness and LV mass index and rapidly improving measurements of diastolic dysfunction. Vutrisiran demonstrated promise as a disease-modifying agent in wild-type and variant ATTR-CM.The SEQUOIA-HCM trial showed favorable effects of aficamten, a next-in-class cardiac myosin inhibitor (CMI), in improving functional capacity while reducing left ventricular outflow tract gradients in patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM)6. A subsequent responder analysis showed improvements in both hemodynamics and symptom status, including 62% of patients in the treatment arm achieving at least 3 of the 4 clinically relevant efficacy measures (rest and Valsalva gradient <30 mm Hg and <50 mm Hg, respectively; ≥1 improvement in NYHA functional class and/or ≥10-point change in KCCQ-CSS; ≥1.5 mL/kg/min change in peak oxygen uptake; ≥50% reduction in NTproBNP) by week 24 of therapy8. A large percentage of patients that were initially guideline eligible for septal reduction therapy at the start of the study were deemed ineligible by the end of the follow up period (88% vs. 52% in placebo, p=0.002). CMI demonstrate encouraging effects on physiologic endpoints; future studies will help determine the benefits on long-term CV outcomes.The EMBARK-HFpEF trial sought to explore the role of mavacamten in patients with HFpEF9. In this Phase 2a, open-label, single-arm trial of 30 patients with symptomatic HFpEF, elevated NT-proBNP levels, and LV hypertrophy, the primary efficacy endpoint was met with a significant decrease in NT-proBNP level by 27% and troponin I by 20% from baseline to 26 weeks in the mavacamten treatment arm. Exploratory analyses of echocardiographic measurements demonstrated improved diastolic function, slight decreases in resting and peak exercise LVEF, and preserved contractile reserve with exercise. Adverse events were low, and three patients discontinued mavacamten due to LVEF reduction >15% or LVEF <50%. Notably, there were no sustained reductions in systolic function after drug discontinuation. The ongoing Phase 2 RCT AURORA-HFpEF will further explore the role of CMI for patients with HFpEF.The ARIES-HM3 trial showed that in patients with advanced HF supported by a HeartMate 3 (HM3) left ventricular assist device (LVAD), exclusion of aspirin and using vitamin K antagonism (VKA) alone did not increase thromboembolic risk and was associated with a reduction in bleeding events10. The use and impact of background medical therapy (including anti-hypertensive medications, heart failure-specific therapy and other cardiovascular drugs) on the composite primary end point was presented. Early initiation of renin-angiotensin-aldosterone-system (RAAS) inhibitors may be linked to a lower incidence of hemocompatibility-related adverse events. Additionally, the study did not confirm earlier findings that suggested associations between the use of statins, PDE5 inhibitors, or digoxin and improved hemocompatibility in these patients.The HuMAIN-HFpEF trial investigated HU6, a novel controlled metabolic accelerator designed to enhance metabolism by activating mitochondrial uncoupling, as a potential treatment for HFpEF in patients with obesity11. This Phase 2a study involved 66 participants, testing different doses of HU6 against a placebo. The primary efficacy endpoint was a change in body weight from baseline to day 134 and a secondary endpoint was change in peak oxygen uptake. In patients with chronic stable obesity-related HFpEF, HU6 was found to be safe, well-tolerated, and led to significant reductions in body weight. This weight loss was accompanied by preservation in lean body mass; however there were no notable improvements in exercise capacity, walking distance, quality of life, or cardiac biomarkers during the short treatment period. Larger, longer-term studies are needed to determine if HU6 can enhance functional status and clinical outcomes in this population.

    Rapid Fire Abstracts

    Rapid fire oral abstract sessions were originally planned to showcase key emerging data. Here, we review a few of these interesting studies.PROACTIVE-HF was a single-arm, multi-center, open label design trial that enrolled NYHA class III HF patients with prior HF hospitalization or elevated natriuretic peptides implanted with a pulmonary artery (PA) pressure sensor (Cordella) to guide therapy12. At 6 months, the incidence of HF hospitalization or all-cause mortality compared to a performance goal (based on prior PA pressure monitoring trials, CHAMPION13 and GUIDE-HF14) was 0.15 vs. 0.43 events/patient/6-month; p<0.001 meeting the primary effectiveness endpoint. At 12 months, the 456 patients managed with Cordella experienced a meaningful reduction in one-year HF hospitalization and all-cause mortality rate (36 events per 100 patients versus the 70 events per 100 patients that were pre specified; 49% lower).The prospective, multicenter, single arm FUTURE-HF2 Trial showed the safety and feasibility of a novel implantable sensor (FIRE1) designed to monitor inferior vena cava (IVC) area for HF patients, allowing for daily volume assessments to predict systemic congestion15. In 15 patients, the device showed excellent accuracy when compared to CT scans (R2=0.99) and had a high patient adherence rate (98%). All patients met primary safety and effectiveness endpoints, and there was a significant improvement in NYHA class.As inflammation has been associated with HF pathogenesis and disease severity, the CORTA-HF trial was a small open-label study evaluating the effects of 7 days of prednisone on inflammatory measures and 90-day clinical outcomes among patients admitted with acute HF and elevated inflammatory markers16. A post-hoc analysis demonstrated greater improvement in congestion score at day 31 in the prednisone arm compared to placebo (win odds for lower congestion score with prednisone 1.77, 95% CI 1.17-2.84)17. A larger magnitude of benefit was observed for patients with a higher baseline interleukin-6 level, with most notable reductions in score driven by improvements in peripheral edema and rales.CARE-HK is the first multinational HF registry enrolling patients with chronic HF at high risk for hyperkalemia (HK)19. This registry enrolled 2558 adults (US n=832, Europe n=1726) with chronic HF treated with angiotensin converting enzyme inhibitor (ACEi), angiotensin receptor blocker (ARB), or angiotensin receptor/neprilysin inhibitor (ARNi), and also receiving or indicated for mineralocorticoid receptor antagonist (MRA), with an increased risk for HK (estimated glomerular filtration rate, eGFR <45 mL/min/1.73m2, current HK [serum K+ >5.0], or history of HK in the previous 24 months). Patients on RRT or MCS were excluded. Over a median prospective follow up time of 12.3 months, 29% had ≥1 HK event (7% had ≥2), 4% had RAASi down-titrated/discontinued within 30 days of the first HK event, and 9% were prescribed patiromer at any point during the study. Twenty-nine percent achieved RAASi optimization during the prospective follow up period. No difference was seen in all-cause mortality (7.0 versus 7.6 events per 100 patient-years for ≥1 HK event group, n=1812, versus no HK event group, n=746). All-cause hospitalization was greater in the ≥1 HK event group versus no HK event group (100 versus 43.2 events per patient years, p<0.001).In addition to groundbreaking clinical science, innovation in academic publishing was also showcased. In 2021, JCF implemented a double-blind peer review process as an exploratory initiative in its efforts to expand authorship diversity and reduce bias in publishing. Initial observations show an increase in the proportion of women as first authors, from 24% prior to double-blind reviews to 39% after implementation of the double-blind review process (p=0.04). The proportion of women as senior authors remained stable over time around 21-22%. Notably, manuscripts with a woman as senior author were significantly more likely to have a woman as first author. Further studies are needed to help determine which initiatives may help advance sustained improvements in diversity in academic publishing18.

    Conclusions

    The HFSA ASM highlighted a vast array of relevant studies in HF. Given the virtual pivot and lack of in-person attendance due to inclement weather, HFSA will certainly be engaging with the HF community over the coming months to share the knowledge from the ASM in different formats. We hope this summary will serve as a launching point for this ongoing dialogue.
    AHDr. Alexander Hajduczok

    Dr. Alexander Hajduczok

    Cardiology · Advanced Heart Failure & Transplantation
    Oklahoma Heart Hospital
    alexanderh